Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

MicuRx Taps China Links To Progress Improved Oxazolidinone

This article was originally published in PharmAsia News

Executive Summary

Multidrug-resistant bacteria have been identified as a major public health threat by the WHO. MicuRx, a Sino-US drug developer, is discovering and developing novel potential first-in-class antibiotics to combat such infections, and is taking an oxazolidinone with expected benefits over same class drugs into Phase III China trials.



Related Companies